Business Wire
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
- Home
- NPCE
NPCE
Neuropace Inc.
as of 12-05-2025 3:43pm EST
$16.36
$0.61
-3.62%
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Chart Type:
Time Range:
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 328.8M | IPO Year: | 2021 |
| Target Price: | $17.00 | AVG Volume (30 days): | 246.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.56 - $18.98 | Next Earning Date: | 11-04-2025 |
| Revenue: | $94,864,000 | Revenue Growth: | 24.08% |
| Revenue Growth (this year): | 24.82% | Revenue Growth (next year): | 1.28% |
AI-Powered NPCE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 72.41%
72.41%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
Compare NPCE vs Leading Stocks
See how NPCE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.